Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Investing Activities (2018 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Cash from Investing Activities for 10 consecutive years, with $227000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 104.15% year-over-year to $227000.0, compared with a TTM value of $18.1 million through Dec 2025, up 181.8%, and an annual FY2025 reading of $18.1 million, up 181.8% over the prior year.
  • Cash from Investing Activities was $227000.0 for Q4 2025 at Zevra Therapeutics, up from -$4.6 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $34.0 million in Q2 2023 and bottomed at -$44.5 million in Q3 2023.
  • Average Cash from Investing Activities over 5 years is -$3.9 million, with a median of -$81000.0 recorded in 2021.
  • The sharpest move saw Cash from Investing Activities crashed 59280.77% in 2021, then surged 16901.59% in 2023.
  • Year by year, Cash from Investing Activities stood at -$15.4 million in 2021, then soared by 99.59% to -$63000.0 in 2022, then soared by 16901.59% to $10.6 million in 2023, then crashed by 151.69% to -$5.5 million in 2024, then soared by 104.15% to $227000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for ZVRA at $227000.0 in Q4 2025, -$4.6 million in Q3 2025, and $11.9 million in Q2 2025.